Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

医学 首脑会议 内科学 来那替尼 肿瘤科 宫颈癌 癌症 曲妥珠单抗 乳腺癌 地图学 地理
作者
Claire F. Friedman,Anishka D’Souza,Diana Bello Roufai,Anna V. Tinker,Maria J. de Miguel,Valentina Gambardella,Jonathan W. Goldman,Sherene Loi,Michelle Melisko,Ana Oaknin,Iben Spanggaard,Geoffrey I. Shapiro,Adam C. ElNaggar,Stefano Panni,Vignesh Ravichandran,Aimee Frazier,Daniel DiPrimeo,Lisa D. Eli,David B. Solit
出处
期刊:Gynecologic Oncology [Elsevier]
卷期号:181: 162-169 被引量:6
标识
DOI:10.1016/j.ygyno.2023.12.004
摘要

Objective HER2 mutations are associated with poor prognosis and are detected in 3–6% of cervical cancers. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, had activity in several HER2-mutant cancer types in the phase 2 SUMMIT basket study. We present updated and final results from the cervical cancer cohort of SUMMIT. Methods Eligible patients had HER2-mutant, metastatic or recurrent cervical cancer progressing after platinum-based treatment for advanced/recurrent disease. Patients received neratinib 240 mg/day; loperamide was mandatory during cycle 1. Confirmed objective response rate (ORR) was the primary endpoint. Duration of response (DoR), clinical benefit rate (CBR), progression-free survival (PFS), and safety were secondary endpoints. Results Twenty-two patients were enrolled; 18 (81.8%) had endocervical adenocarcinoma; median two prior systemic chemotherapy regimens (range 1–4). The most common HER2 variant was S310F/Y mutation (n = 13; 59.1%). Four patients had confirmed partial responses (ORR 18.2%; 95% CI 5.2–40.3); 6 had stable disease ≥16 weeks (CBR 45.5%; 95% CI 24.4–67.8). Median DoR was 7.6 months (95% CI 5.6–12.3). Median PFS was 5.1 months (95% CI 1.7–7.2). All-grade diarrhea (90.9%), nausea (54.5%), and constipation (54.5%) were the most common adverse events. Five patients (22.7%) reported grade 3 diarrhea. There were no grade 4 adverse events, no diarrhea-related treatment discontinuations, and two grade 5 adverse events, unrelated to neratinib: dyspnea (n = 1) and embolism (n = 1). Conclusions Neratinib resulted in durable responses and disease control in patients with HER2-mutant metastatic/recurrent cervical cancer in SUMMIT. These findings support next-generation sequencing and tailored therapy for select patients with advanced cervical cancer. All responses occurred in patients with endocervical adenocarcinoma. Further assessment of neratinib in this setting is warranted. Trial registration number. NCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI

祝大家在新的一年里科研腾飞
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
nicolaslcq完成签到,获得积分10
刚刚
小蘑菇完成签到,获得积分10
刚刚
sfdf发布了新的文献求助10
刚刚
手机应助禹无极采纳,获得10
刚刚
TszPok完成签到,获得积分10
3秒前
3秒前
ding应助Willow采纳,获得10
3秒前
4秒前
4秒前
5秒前
充电宝应助Lin_Yongqi采纳,获得10
5秒前
wanci应助雪碧采纳,获得10
6秒前
gying应助Hammerdai采纳,获得10
6秒前
111发布了新的文献求助10
9秒前
liaoliaoliao完成签到,获得积分10
9秒前
9秒前
xch发布了新的文献求助10
11秒前
无花果应助纠纠采纳,获得10
12秒前
12秒前
爆米花应助John采纳,获得10
14秒前
汉堡包应助可靠的秋尽采纳,获得10
15秒前
古铜麦麦应助WYX采纳,获得10
15秒前
15秒前
雪糕发布了新的文献求助30
15秒前
16秒前
maasai完成签到,获得积分10
16秒前
杳鸢应助季末默相依采纳,获得10
16秒前
夏漆应助雪碧采纳,获得10
16秒前
shelemi发布了新的文献求助10
16秒前
jijibao发布了新的文献求助10
19秒前
hahhahah发布了新的文献求助10
21秒前
英勇太君发布了新的文献求助10
21秒前
jindou完成签到,获得积分10
21秒前
深情安青应助ppxx采纳,获得10
23秒前
23秒前
24秒前
璇222发布了新的文献求助10
24秒前
科研通AI2S应助tzq采纳,获得10
25秒前
卓矢完成签到 ,获得积分10
25秒前
sx19910304发布了新的文献求助10
26秒前
高分求助中
Востребованный временем 2500
The Three Stars Each: The Astrolabes and Related Texts 1500
Agenda-setting and journalistic translation: The New York Times in English, Spanish and Chinese 1000
Les Mantodea de Guyane 1000
Very-high-order BVD Schemes Using β-variable THINC Method 950
Field Guide to Insects of South Africa 660
Foucault's Technologies Another Way of Cutting Reality 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3391142
求助须知:如何正确求助?哪些是违规求助? 3002415
关于积分的说明 8803867
捐赠科研通 2689027
什么是DOI,文献DOI怎么找? 1472855
科研通“疑难数据库(出版商)”最低求助积分说明 681265
邀请新用户注册赠送积分活动 674109